HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma.

Abstract
Clear cell renal cell carcinoma (ccRCC) is an aggressive disease with unpredictable behaviour. Clinical parameters are not always accurate for prognosis prediction. The integration of molecular markers to prognostic models can significantly improve prognostic assessment and consequently patient management. We assessed the expression of alpha-enolase (ENO1) protein by immunohistochemistry in 360 patients with primary ccRCC and correlated its expression with multiple clinicopathological parameters including stage, grade, tumor size, disease-free and overall survival. Cox proportional hazard regression models adjusted for clinicopathological factors were used to test for a link between ENO1 expression and both disease-free and overall survival. We correlated ENO1 mRNA expression with overall survival in an independent set of 428 ccRCC cases from The Cancer Genome Atlas. ENO1 showed cytoplasmic, membranous and nuclear staining patterns. There is a statistically significant negative correlation between ENO1 expression, tumor stage, and grade. ENO1 expression also shows a statistically significant direct correlation with disease-free survival (p = 0.011) and overall survival (p = 0.030) in ccRCC. Patients with higher ENO1 expression had lower hazard ratio of recurrence, although this was not statistically significant (HR = 0.330, p = 0.060). These findings were validated at the mRNA level in an independent set of 428 ccRCC cases which also showed that low ENO1 expression is associated with significantly shorter overall survival. Down-regulation of ENO1 can be a predictor of poor prognosis in ccRCC, and it can be a potential prognostic marker.
AuthorsNicole M White-Al Habeeb, Ashley Di Meo, Andreas Scorilas, Fabio Rotondo, Olena Masui, Annetta Seivwright, Manal Gabril, Andrew H A Girgis, Michael A Jewett, George M Yousef
JournalClinical & experimental metastasis (Clin Exp Metastasis) Vol. 32 Issue 6 Pg. 531-41 (Aug 2015) ISSN: 1573-7276 [Electronic] Netherlands
PMID26037892 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
  • DNA-Binding Proteins
  • MicroRNAs
  • RNA, Messenger
  • Tumor Suppressor Proteins
  • ENO1 protein, human
  • Phosphopyruvate Hydratase
Topics
  • Biomarkers, Tumor (genetics, metabolism)
  • Carcinoma, Renal Cell (genetics, metabolism, mortality, pathology)
  • Cohort Studies
  • DNA-Binding Proteins (genetics, metabolism)
  • Follow-Up Studies
  • Humans
  • Immunoenzyme Techniques
  • Kidney Neoplasms (genetics, metabolism, mortality, pathology)
  • MicroRNAs (genetics)
  • Neoplasm Grading
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local (genetics, metabolism, mortality, pathology)
  • Neoplasm Staging
  • Phosphopyruvate Hydratase (genetics, metabolism)
  • Prognosis
  • RNA, Messenger (genetics)
  • Real-Time Polymerase Chain Reaction
  • Reverse Transcriptase Polymerase Chain Reaction
  • Survival Rate
  • Tumor Cells, Cultured
  • Tumor Suppressor Proteins (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: